Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD
By Colin Kellaher
Amgen on Wednesday said a late-stage study of its autoimmune drug Uplizna hit its key goals in the treatment of immunoglobulin G4-related disease, a chronic, immune-mediated disease known as IgG4-RD.
Amgen said the Phase 3 study met its primary endpoint, showing a statistically significant 87% reduction in the risk of IgG4-RD flare compared to placebo, as well as key secondary endpoints.
The Thousand Oaks, Calif., biotechnology company said it plans to seek U.S. Food and Drug Administration approval of Uplizna in IgG4-RD, followed by other key markets.
Uplizna is currently approved in the U.S., Europe and several other countries for the rare autoimmune disease neuromyelitis optica spectrum disorder.
Amgen acquired Uplizna as part of its $27.8 billion acquisition of Horizon Therapeutics last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 05, 2024 09:43 ET (13:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What’s Happening In the Markets This Week
-
What a Strong Economy Now Means for the Rest of 2024
-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
10 Undervalued Wide-Moat Stocks
-
What Is a Stock Split?
-
Investment Opportunities in US Renewable Energy
-
10 Best Value Stocks to Buy for the Long Term
-
A Wide-Moat Stock to Invest in That’s 35% Undervalued
-
Airbus: We Believe Investors May Be Overreacting to Lowered Guidance and Charge
-
10 Stocks the Best Fund Managers Have Been Selling
-
TSMC Fair Value Raised 45% on Stronger AI Demand